SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2022 / Cilt: 6 - Sayı: 2

Clinicopathologic Features of Operated Gastrointestinal Stromal Tumors, Adjuvant Therapy Outcomes, and Recurrence-Related Factors

Aysegül İLHAN
Emrah ERASLAN
Nazan DEMİR
Ferit ASLAN
Pages
210–216
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Increased aged at diagnosis (HR=0.952, 95% CI 0.910-0.995, p=0.030), Ki-67

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We aimed to evaluate the clinicopathological features and clinical outcomes of patients with resected Gastrointestinal stromal tumors (GISTs).
📊
Key Findings & Data:Patients diagnosed with a GIST, 18 years of age and older, operated on R0, between January 2005 and May 2020 were included in the study.
💡
Conclusion & Impact:Increased aged at diagnosis (HR=0.952, 95% CI 0.910-0.995, p=0.030), Ki-67
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: We aimed to evaluate the clinicopathological features and clinical outcomes of patients with resected Gastrointestinal stromal tumors (GISTs). Methods: This study was a retrospective, multicenter cohort study. Patients diagnosed with a GIST, 18 years of age and older, operated on R0, between January 2005 and May 2020 were included in the study. Patient with metastatic disease at diagnosis were excluded. Results: Of 104 patients, the median age was 61 years (35-87) and 58.7% (n=61) were male. The most common location was stomach (n=52.5%). According to The Modified-National Institutes of Health (M-NIH) classifications, 52 (50%) patients were in the high-risk group. The median relapse-free survival (RFS) was 62.1 (95% CI; 52.7-71.5) months. Increased aged at diagnosis (HR=0.952, 95% CI 0.910-0.995, p=0.030), Ki-67

🔖

Cite This Article

İLHAN, A., ERASLAN, E., DEMİR, N., ASLAN, F. (2022). Clinicopathologic Features of Operated Gastrointestinal Stromal Tumors, Adjuvant Therapy Outcomes, and Recurrence-Related Factors. Eurasian Journal of Medical Investigation, Cilt: 6 - Sayı: 2, 210–216. https://ajindex.com/articles/508527

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Mucciarini C, Rossi G, Bertolini F, Valli R, Cirilli C, Rashid I, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007;7:230
  2. Supsamutchai C, Wilasrusmee C, Hiranyatheb P, Jirasiritham J, Rakchob T, Choikrua P. A cohort study of prognostic factors associated with recurrence or metastasis of gastrointestinal stromal tumor (GIST) of stomach. Ann Med Surg (Lond) 2018;35:1–5
  3. Boukovinas I, Kotsakis A, Androulakis N, Aravantinos G, Michalaki V, Christodoulou C, et al. Recurrence-free survival and safety of imatinib in patients with gastrointestinal stromal tumour (GIST) in Greece. Anticancer Res 2020;40:435–41
  4. Nowain A, Bhakta H, Pais S, Kanel G, Verma S. Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol 2005;20:818–24
  5. Bülbül Doğusoy G; Turkish GIST Working Group. Gastrointestinal stromal tumors: A multicenter study of 1160 Turkish cases. Turk J Gastroenterol 2012;23:203–11
  6. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002;10:81–9
  7. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70–83
  8. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097–104
  9. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307:1265–72. 10. von Mehren M, Kane JM, Bui MM, Choy E, Connelly M, Dry S, et al. NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw 2020;18:1604–12
  10. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol 2016;40:39–46
  11. Wang M, Xu J, Zhang Y, Tu L, Qiu WQ, Wang CJ, et al. Gastrointestinal stromal tumor: 15-years' experience in a single center. BMC Surg 2014;14:93
  12. Ahmed M. Recent advances